Important Deadline for Unicycive Therapeutics Inc. Class Action Announced

Attention Unicycive Investors: Class Action Notice

On October 8, 2026, SueWallSt alerted stakeholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) about an impending securities class action. This action is on behalf of investors who bought Unicycive shares between December 29, 2025, and June 29, 2026. As we approach the November 2, 2026 deadline for appointing a lead plaintiff, understanding the context of this case is crucial for affected investors.

Background of the Allegations

The lawsuit centers around accusations that Unicycive Therapeutics misled its investors regarding the progress of its third-party manufacturing vendor in regaining FDA compliance. Specifically, the complaint argues that the company claimed that its vendor had made "significant progress" toward compliance without verifying this assertion through its own inspection methods. This situation became particularly concerning when, on June 30, 2026, it was revealed that the expected compliance had not been substantiated, causing Unicycive's stock to plummet by 39.1%, equating to a drop of $3.01 per share.

Implications of the First Complete Response Letter

The initial announcement on December 29, 2025, informed investors that Unicycive had submitted the 505(b)(2) New Drug Application for oxylanthanum carbonate. In this announcement, management cited the vendor's claimed progress. However, the class action asserts that these claims were not supported by any substantive audits or inspections of the vendor’s manufacturing facility. The lawsuit highlights that the company had failed to confirm whether the deficiencies mentioned in the June 2025 Complete Response Letter were rectified.

During the class period, investors were left vulnerable due to a lack of transparency surrounding these critical vendor compliance issues. The belief held by Unicycive management that their vendor was making progress was not corroborated by any audits, which led to significant misrepresentations that purportedly influenced investment decisions.

Consequences of Misleading Information

Following disclosures of the FDA issuing a second Complete Response Letter based on the same manufacturing deficiencies, shares of UNCY experienced a significant decline. The lawsuit claims that such statements regarding the manufacturing vendor were catastrophically misleading, causing investors who had purchased shares during this misleading period to face considerable financial losses.

How Investors Can Respond

Affected investors should gather their brokerage records indicating purchase dates and quantities, as this documentation will be essential for any recovery claims. Notably, those who sold UNCY shares at a loss during the class period are still eligible to recover losses based on their purchase period.

Important Dates and Procedures

To be part of the legal proceedings, investors wishing to serve as lead plaintiffs must apply by November 2, 2026. Even if investors opt not to take this step, they may still benefit from any eventual settlement without needing to take immediate action.

Investors may want to reach out to SueWallSt, represented by Joseph E. Levi, Esq., for no-cost, no-obligation evaluations of their potential claims. Their investments may entitle them to recover damages without upfront costs, as securities litigation generally proceeds on a contingency basis.

Summary

Unicycive Therapeutics, Inc. has attracted investors' scrutiny due to its alleged lack of transparency regarding FDA compliance. As legal proceedings unfold, it's imperative for affected investors to stay informed about crucial deadlines and consider their next steps. This situation exemplifies the importance of due diligence and honest communication in the financial ecosystem.